300318 博晖创新
已收盘 11-22 15:00:00
资讯
新帖
简况
博晖创新（300318）2024年三季报简析：净利润增67.77%，盈利能力上升
证券之星 · 10-31
博晖创新（300318）2024年三季报简析：净利润增67.77%，盈利能力上升
图解博晖创新三季报：第三季度单季净利润同比减147.69%
证券之星 · 10-30
图解博晖创新三季报：第三季度单季净利润同比减147.69%
博晖创新(300318.SZ)发布前三季度业绩，净利润2371.77万元，增长67.77%
智通财经 · 10-29
博晖创新(300318.SZ)发布前三季度业绩，净利润2371.77万元，增长67.77%
源达研究报告：血液制品行业盈利水平改善，未来成长空间广阔
市场资讯 · 10-11
源达研究报告：血液制品行业盈利水平改善，未来成长空间广阔
博晖创新(300318.SZ)孙公司廊坊博晖终止与柏奥特克项目合作合同
智通财经 · 09-24
博晖创新(300318.SZ)孙公司廊坊博晖终止与柏奥特克项目合作合同
博晖创新最新公告：控股孙公司终止项目合作合同及药物临床试验
证券之星 · 09-24
博晖创新最新公告：控股孙公司终止项目合作合同及药物临床试验
博晖创新(300318.SZ)：下属浆站取得单采血浆许可证
智通财经 · 09-11
博晖创新(300318.SZ)：下属浆站取得单采血浆许可证
博晖创新最新公告：获得医疗器械注册证
证券之星 · 09-10
博晖创新最新公告：获得医疗器械注册证
博晖创新(300318.SZ)获“呼吸道病原体六重核酸检测试剂盒”医疗器械注册证
智通财经 · 09-10
博晖创新(300318.SZ)获“呼吸道病原体六重核酸检测试剂盒”医疗器械注册证
博晖创新：9月3日接受机构调研，华夏基金管理有限公司、上海申银万国证券研究所有限公司等多家机构参与
证券之星 · 09-03
博晖创新：9月3日接受机构调研，华夏基金管理有限公司、上海申银万国证券研究所有限公司等多家机构参与
博晖创新（300318）2024年中报简析：净利润增366.35%，盈利能力上升
证券之星 · 08-31
博晖创新（300318）2024年中报简析：净利润增366.35%，盈利能力上升
图解博晖创新中报：第二季度单季净利润同比增934.19%
证券之星 · 08-30
图解博晖创新中报：第二季度单季净利润同比增934.19%
博晖创新最新公告：2024年上半年净利润2763.38万元 同比增长366.35%
证券之星 · 08-29
博晖创新最新公告：2024年上半年净利润2763.38万元 同比增长366.35%
博晖创新(300318.SZ)发上半年业绩，净利润2763.38万元，同比增长366.35%
智通财经 · 08-29
博晖创新(300318.SZ)发上半年业绩，净利润2763.38万元，同比增长366.35%
A股疫苗股震荡走低，金迪克跌超10%，康希诺、华兰疫苗、蔚蓝生物、百克生物、博晖创新等跟跌。
美港电讯 · 08-28
A股疫苗股震荡走低，金迪克跌超10%，康希诺、华兰疫苗、蔚蓝生物、百克生物、博晖创新等跟跌。
博晖创新（300318）8月27日主力资金净卖出114.56万元
证券之星 · 08-27
博晖创新（300318）8月27日主力资金净卖出114.56万元
博晖创新（300318）8月22日主力资金净卖出529.29万元
证券之星 · 08-22
博晖创新（300318）8月22日主力资金净卖出529.29万元
博晖创新（300318）8月20日主力资金净卖出1020.04万元
证券之星 · 08-20
博晖创新（300318）8月20日主力资金净卖出1020.04万元
博晖创新：目前公司猴痘相关检测试剂盒只取得了欧盟CE认证，产品尚未上市销售
证券之星 · 08-16
博晖创新：目前公司猴痘相关检测试剂盒只取得了欧盟CE认证，产品尚未上市销售
A股午后猴痘概念持续拉升，海辰药业、亚太药业2连板，透景生命、普利制药、合富中国涨停，博晖创新、优宁维、之江生物、迈克生物等多股涨超5%。
美港电讯 · 08-16
A股午后猴痘概念持续拉升，海辰药业、亚太药业2连板，透景生命、普利制药、合富中国涨停，博晖创新、优宁维、之江生物、迈克生物等多股涨超5%。
加载更多
公司概况
公司名称：
北京博晖创新生物技术集团股份有限公司
所属行业：
专用设备制造业
上市日期：
2012-05-23
主营业务：
北京博晖创新生物技术集团股份有限公司的主营业务为检验检测业务及生物制品业务。公司主要产品有HPV检测产品、微量元素检测产品、质谱相关检测产品、其他耗材及服务、人血白蛋白、静注人免疫球蛋白、其他血液制品。
发行价格：
15.00
{"stockData":{"symbol":"300318","market":"SZ","secType":"STK","nameCN":"博晖创新","latestPrice":6.21,"timestamp":1732259001000,"preClose":6.68,"halted":0,"volume":21672456,"delay":0,"floatShares":799000000,"shares":817000000,"eps":-0.0188,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.47,"latestTime":"11-22 15:00:00","open":6.71,"high":6.76,"low":6.2,"amount":139000000,"amplitude":0.0838,"askPrice":6.22,"askSize":497,"bidPrice":6.21,"bidSize":1404,"shortable":0,"etf":0,"ttmEps":-0.0188,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":6.68,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":7.35,"lowLimit":6.01,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":816900495,"pbRate":3.92,"roa":"--","roe":"1.72%","epsLYR":-0.0305,"committee":0.551091,"marketValue":5073000000,"floatMarketCap":4959000000,"peRate":-330.319154,"changeRate":-0.0704,"turnoverRate":0.0271,"status":1},"requestUrl":"/m/hq/s/300318","defaultTab":"news","newsList":[{"id":"2479760036","title":"博晖创新（300318）2024年三季报简析：净利润增67.77%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479760036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479760036?lang=zh_cn&edition=full","pubTime":"2024-10-31 06:40","pubTimestamp":1730328053,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博晖创新发布2024年三季报。截至本报告期末，公司营业总收入6.46亿元，同比下降19.85%，归母净利润2371.77万元，同比上升67.77%。本报告期博晖创新盈利能力上升，毛利率同比增幅13.32%，净利率同比增幅125.14%。去年的净利率为1.5%，算上全部成本后，公司产品或服务的附加值不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100009333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318"],"gpt_icon":0},{"id":"2479232843","title":"图解博晖创新三季报：第三季度单季净利润同比减147.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479232843","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479232843?lang=zh_cn&edition=full","pubTime":"2024-10-30 01:30","pubTimestamp":1730223028,"startTime":"0","endTime":"0","summary":"证券之星消息，博晖创新2024年三季报显示，公司主营收入6.46亿元，同比下降19.85%；归母净利润2371.77万元，同比上升67.77%；扣非净利润1565.64万元，同比上升29.24%；其中2024年第三季度，公司单季度主营收入1.59亿元，同比下降42.99%；单季度归母净利润-391.6万元，同比下降147.69%；单季度扣非净利润-1068.17万元，同比下降255.04%；负债率42.03%，投资收益117.05万元，财务费用2017.62万元，毛利率50.65%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000000974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318"],"gpt_icon":0},{"id":"2479847612","title":"博晖创新(300318.SZ)发布前三季度业绩，净利润2371.77万元，增长67.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479847612","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479847612?lang=zh_cn&edition=full","pubTime":"2024-10-29 22:55","pubTimestamp":1730213709,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博晖创新(300318.SZ)发布2024年三季度报告，该公司前三季度营业收入为6.46亿元，同比减少19.85%。归属于上市公司股东的净利润为2371.77万元，同比增长67.77%。归属于上市公司股东的扣除非经常性损益的净利润为1565.64万元，同比增长29.24%。基本每股收益为0.029元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1203077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300318"],"gpt_icon":0},{"id":"2474050430","title":"源达研究报告：血液制品行业盈利水平改善，未来成长空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2474050430","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474050430?lang=zh_cn&edition=full","pubTime":"2024-10-11 16:55","pubTimestamp":1728636900,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 血液制品属于生物制品行业的细分行业，主要以健康人血浆或经特异免疫的人血浆为原料，采用生物学工艺或分离纯化技术制备的生物活性制剂，是不可或缺的国家重要战略性储备物资及重大疾病急救药品。根据北京欧立信调研中心统计数据，2023年我国血液制品市场规模超500亿元，预计到2030年我国血液制品市场规模将达到950亿元。行业盈利水平显著改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/roll/2024-10-11/doc-incseqcx5094529.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2024-10-11/doc-incseqcx5094529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0168","BK0196","BK0239","BK0185","300294","002880","BK0046","BK0048","BK0010","BK0197","BK0071","002252","600161","BK0188","BK0028","300318","BK0082","BK0251","000403"],"gpt_icon":0},{"id":"2469463183","title":"博晖创新(300318.SZ)孙公司廊坊博晖终止与柏奥特克项目合作合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2469463183","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469463183?lang=zh_cn&edition=full","pubTime":"2024-09-24 18:06","pubTimestamp":1727172361,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博晖创新 公告，公司控股孙公司博晖生物制药股份有限公司与成都柏奥特克生物科技股份有限公司于2020年1月签订《项目合作合同》，就柏奥特克完成了临床前研究工作的冻干人用狂犬病疫苗进行联合申报。近日，廊坊博晖收到柏奥特克支付的全部补偿款项，《项目合作合同》正式终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1186491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0251","300318","BK0048"],"gpt_icon":0},{"id":"2469463186","title":"博晖创新最新公告：控股孙公司终止项目合作合同及药物临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2469463186","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469463186?lang=zh_cn&edition=full","pubTime":"2024-09-24 17:59","pubTimestamp":1727171999,"startTime":"0","endTime":"0","summary":"博晖创新公告，控股孙公司廊坊博晖与柏奥特克及其他相关方签订补充协议，约定满足条件后，终止双方于2020年1月签订的项目合作合同，并终止双方合作研发的冻干人用狂犬病疫苗（无血清Vero细胞）的临床试验。柏奥特克同意向廊坊博晖补偿人民币1,800万元。本次终止临床试验不会影响公司对人用狂犬病疫苗技术平台的持续布局，不会对公司其他在研项目的研发工作产生影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092400029552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","03347","BK0028","300318","BK1576","BK1583","BK0048","BK0251"],"gpt_icon":0},{"id":"2466709614","title":"博晖创新(300318.SZ)：下属浆站取得单采血浆许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2466709614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466709614?lang=zh_cn&edition=full","pubTime":"2024-09-11 17:13","pubTimestamp":1726046021,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博晖创新(300318.SZ)公告，近日，公司控股子公司博晖生物制药(河北)有限公司下属大关博晖单采血浆有限公司(“大关浆站”)取得云南省卫生健康委员会颁发的《单采血浆许可证》，大关浆站经核准登记，准予执业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1181953.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300318","BK0028","BK0048","BK0251"],"gpt_icon":0},{"id":"2466489610","title":"博晖创新最新公告：获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2466489610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466489610?lang=zh_cn&edition=full","pubTime":"2024-09-10 16:57","pubTimestamp":1725958634,"startTime":"0","endTime":"0","summary":"博晖创新公告，公司近日获得国家药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》。产品名称为呼吸道病原体六重核酸检测试剂盒（PCR-荧光探针法），注册分类为Ⅲ类，注册证有效期为2024年9月10日至2029年9月9日。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024091000026286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159883","09996","BK1583","300318","09997","BK1574","BK0251","BK0048","BK0028","BK1100","BK1222"],"gpt_icon":0},{"id":"2466485227","title":"博晖创新(300318.SZ)获“呼吸道病原体六重核酸检测试剂盒”医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2466485227","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2466485227?lang=zh_cn&edition=full","pubTime":"2024-09-10 16:39","pubTimestamp":1725957562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博晖创新(300318.SZ)公告，公司近日获得由国家药品监督管理局颁发的《中华人民共和国医疗器械注册证(体外诊断试剂)》，产品名称：呼吸道病原体六重核酸检测试剂盒(PCR-荧光探针法)。据悉，该产品用于定性检测人咽拭子样本中的呼吸道病原体，包括甲型流感病毒(季节性H1N1、新型甲型H1N1流感病毒(2009)、H3N2、H5N1、H7N9)、乙型流感病毒(Victoria系和Yamagata系)、腺病毒(B组、C组、E组)、呼吸道合胞病毒(A亚型和B亚型)、肺炎支原体和百日咳鲍特菌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1181384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09997","BK1222","BK1100","300318","BK1583","BK0251","09996","BK0028","159883","BK0048"],"gpt_icon":0},{"id":"2464802255","title":"博晖创新：9月3日接受机构调研，华夏基金管理有限公司、上海申银万国证券研究所有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2464802255","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464802255?lang=zh_cn&edition=full","pubTime":"2024-09-03 21:54","pubTimestamp":1725371677,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年9月3日博晖创新发布公告称公司于2024年9月3日接受机构调研，华夏基金管理有限公司王泽实 孙明达 常黎曼、上海申银万国证券研究所有限公司凌静怡、申万宏源证券有限公司吕静静参与。受行业批签发下降的影响，静丙需求较其他血制品处于较高水平。公司上述各类产品价格根据不同渠道及终端，有一定浮动。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090300037793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300318","BK0251","BK0028","BK0048"],"gpt_icon":0},{"id":"2463671578","title":"博晖创新（300318）2024年中报简析：净利润增366.35%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2463671578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463671578?lang=zh_cn&edition=full","pubTime":"2024-08-31 06:29","pubTimestamp":1725056964,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博晖创新发布2024年中报。截至本报告期末，公司营业总收入4.87亿元，同比下降7.6%，归母净利润2763.38万元，同比上升366.35%。本报告期博晖创新盈利能力上升，毛利率同比增幅29.14%，净利率同比增幅1761.13%。其中，毛利率51.08%，同比增29.14%，净利率11.58%，同比增1761.13%，销售费用、管理费用、财务费用总计1.42亿元，三费占营收比29.16%，同比减2.34%，每股净资产1.71元，同比减0.28%，每股经营性现金流0.02元，同比减78.2%，每股收益0.03元，同比增363.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083100009155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318"],"gpt_icon":0},{"id":"2463295870","title":"图解博晖创新中报：第二季度单季净利润同比增934.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463295870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463295870?lang=zh_cn&edition=full","pubTime":"2024-08-30 01:58","pubTimestamp":1724954329,"startTime":"0","endTime":"0","summary":"证券之星消息，博晖创新2024年中报显示，公司主营收入4.87亿元，同比下降7.6%；归母净利润2763.38万元，同比上升366.35%；扣非净利润2633.81万元，同比上升404.11%；其中2024年第二季度，公司单季度主营收入2.25亿元，同比下降17.93%；单季度归母净利润777.02万元，同比上升934.19%；单季度扣非净利润797.18万元，同比上升735.3%；负债率40.3%，财务费用1173.7万元，毛利率51.08%。财报数据概要请见下图: 以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000003039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318"],"gpt_icon":0},{"id":"2463289244","title":"博晖创新最新公告：2024年上半年净利润2763.38万元 同比增长366.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463289244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463289244?lang=zh_cn&edition=full","pubTime":"2024-08-29 17:22","pubTimestamp":1724923324,"startTime":"0","endTime":"0","summary":"博晖创新发布2024年半年度报告，报告期内，公司实现营业收入4.87亿元，同比下降7.60%；归属于上市公司股东的净利润2763.38万元，同比增长366.35%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082900032514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318"],"gpt_icon":0},{"id":"2463285406","title":"博晖创新(300318.SZ)发上半年业绩，净利润2763.38万元，同比增长366.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463285406","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463285406?lang=zh_cn&edition=full","pubTime":"2024-08-29 17:02","pubTimestamp":1724922139,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博晖创新(300318.SZ)发布2024年半年度报告，报告期内公司实现营业收入4.87亿元，同比减少7.60%;归属于上市公司股东的净利润2763.38万元，同比增长366.35%;归属于上市公司股东扣除非经常性损益净利润2633.81万元，同比增长404.11%;基本每股收益0.0338元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1174752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300318"],"gpt_icon":0},{"id":"2462717504","title":"A股疫苗股震荡走低，金迪克跌超10%，康希诺、华兰疫苗、蔚蓝生物、百克生物、博晖创新等跟跌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2462717504","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462717504?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:45","pubTimestamp":1724809504,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["603739","688276","159982","399300","301207","BK0028","BK0226","BK0251","688185","300318","BK0048","BK0239","688670","159646"],"gpt_icon":0},{"id":"2462139190","title":"博晖创新（300318）8月27日主力资金净卖出114.56万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462139190","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462139190?lang=zh_cn&edition=full","pubTime":"2024-08-27 15:20","pubTimestamp":1724743231,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月27日收盘，博晖创新报收于4.97元，上涨2.47%，换手率1.83%，成交量14.63万手，成交额7340.82万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：博晖创新2024年一季报显示，公司主营收入2.62亿元，同比上升3.6%；归母净利润1986.36万元，同比上升283.9%；扣非净利润1836.63万元，同比上升330.1%；负债率40.21%，财务费用626.94万元，毛利率49.55%。博晖创新主营业务：检验检测及生物制品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082700019536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300318","BK0048","BK0028","BK0251"],"gpt_icon":0},{"id":"2461365897","title":"博晖创新（300318）8月22日主力资金净卖出529.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461365897","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461365897?lang=zh_cn&edition=full","pubTime":"2024-08-22 15:27","pubTimestamp":1724311633,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月22日收盘，博晖创新报收于4.83元，下跌4.73%，换手率2.22%，成交量17.7万手，成交额8744.47万元。8月22日的资金流向数据方面，主力资金净流出529.29万元，占总成交额6.05%，游资资金净流出275.68万元，占总成交额3.15%，散户资金净流入804.96万元，占总成交额9.21%。博晖创新主营业务：检验检测及生物制品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200021053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","300318","BK0251","BK0028"],"gpt_icon":0},{"id":"2460343023","title":"博晖创新（300318）8月20日主力资金净卖出1020.04万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460343023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460343023?lang=zh_cn&edition=full","pubTime":"2024-08-20 15:25","pubTimestamp":1724138748,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月20日收盘，博晖创新报收于5.35元，下跌4.46%，换手率3.51%，成交量28.04万手，成交额1.54亿元。8月20日的资金流向数据方面，主力资金净流出1020.04万元，占总成交额6.61%，游资资金净流出139.27万元，占总成交额0.9%，散户资金净流入1159.31万元，占总成交额7.51%。博晖创新主营业务：检验检测及生物制品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082000019063.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300318","BK0048","BK0251"],"gpt_icon":0},{"id":"2459297861","title":"博晖创新：目前公司猴痘相关检测试剂盒只取得了欧盟CE认证，产品尚未上市销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2459297861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459297861?lang=zh_cn&edition=full","pubTime":"2024-08-16 19:01","pubTimestamp":1723806085,"startTime":"0","endTime":"0","summary":"证券之星消息，博晖创新08月16日在投资者关系平台上答复投资者关心的问题。请董秘回复，谢谢！目前公司猴痘相关检测试剂盒只取得了欧盟CE认证，产品尚未上市销售。截至目前，公司没有处置相关资产的计划，相关事项如有动向将严格履行相关的流程并进行披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081600043991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0048","BK0251","300318","BK0028"],"gpt_icon":0},{"id":"2459522952","title":"A股午后猴痘概念持续拉升，海辰药业、亚太药业2连板，透景生命、普利制药、合富中国涨停，博晖创新、优宁维、之江生物、迈克生物等多股涨超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2459522952","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459522952?lang=zh_cn&edition=full","pubTime":"2024-08-16 13:44","pubTimestamp":1723787075,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300642","301166","688317","BK0028","BK0251","159982","399300","BK0132","300463","BK0250","BK0012","BK0046","BK0239","300318","603122","BK0048","300630","BK0042","300584","002370"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2012-05-23","address":"北京市昌平区生命园路9号","stockEarnings":[{"period":"1week","weight":0.035},{"period":"1month","weight":0.0472},{"period":"3month","weight":0.2857},{"period":"6month","weight":0.1458},{"period":"1year","weight":-0.049},{"period":"ytd","weight":-0.0048}],"companyName":"北京博晖创新生物技术集团股份有限公司","boardCode":"AI0035","perCapita":"23660股","boardName":"专用设备制造业","registeredCapital":"81690万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 北京博晖创新生物技术集团股份有限公司的主营业务为检验检测业务及生物制品业务。公司主要产品有HPV检测产品、微量元素检测产品、质谱相关检测产品、其他耗材及服务、人血白蛋白、静注人免疫球蛋白、其他血液制品。","serverTime":1732344122895,"listedPrice":15,"stockholders":"33750人(较上一季度增加2.62%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博晖创新(300318)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博晖创新(300318)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博晖创新,300318,博晖创新股票,博晖创新股票老虎,博晖创新股票老虎国际,博晖创新行情,博晖创新股票行情,博晖创新股价,博晖创新股市,博晖创新股票价格,博晖创新股票交易,博晖创新股票购买,博晖创新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博晖创新(300318)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博晖创新(300318)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}